Ribavirin post-exposure prophylaxis for Andes virus exposure: a viewpoint

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Andes virus (ANDV) is a unique hantavirus with potential for human-to-human transmission.
• ANDV has a high case fatality rate, necessitating consideration of post-exposure prophylaxis (PEP).
• Ribavirin shows in vitro and animal model efficacy against hantaviruses, but clinical data for ANDV PEP is scarce.

Purpose of the Study:

• To review current evidence on ribavirin as PEP for potential ANDV exposure.
• To identify knowledge gaps affecting ribavirin PEP applicability.
• To inform decisions regarding ribavirin use for ANDV PEP.

Main Methods:

• Literature review of existing evidence on ribavirin for ANDV PEP.
• Discussion of knowledge gaps and limitations.
• Modeling and simulation to visualize potential dosing strategies.

Main Results:

• The biological rationale for ribavirin PEP is compelling.
• Clinical evidence supporting ribavirin for ANDV PEP is extremely limited.
• Potential dosing strategies were modeled, but optimal dose and duration require further study.

Conclusions:

• Ribavirin PEP for ANDV is currently limited to highly selected exposure scenarios.
• The absence of controlled human studies and concerns about potential toxicity restrict its use.
• Further research is needed to establish the efficacy and safety of ribavirin for ANDV PEP.